GlaxoSmithKline: FDA Joint Advisory Committee sets date to review the co's proposal for orlistat 60(mg) capsules for over-the-counter use (GSK) 50.83 +0.15:Co announces that on Jan 23, 2006, the U.S. Food and Drug Administration's joint Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committees will review the New Drug Application for proposed over-the-counter use of orlistat (tetrahydrolipstatin) 60(mg) capsules in the U.S., to promote weight loss in overweight adults when used along with a reduced calorie, low-fat diet.